NCT06837961

LC-Plasma on Immune Response and Reducing Symptoms of Upper Respiratory Infectious Diseases

The Effects of Lactococcus Lactis JCM 5805 (LC-Plasma) Lactic Acid Bacteria on Immune Response and Reducing Symptoms of Upper Respiratory Infectious Disease in Australian Healthy Adults. Randomized Placebo-controlled Double-blind Parallel Group Study.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 241 (actual)
• Sponsor: RDC Clinical Pty Ltd · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The goal of this study is to evaluate the effects of LC-Plasma on the innate and acquired immune systems, including the activation of pDCs, which play a role in virus elimination, as well as to assess its efficacy in reducing clinical symptoms of upper respiratory infectious diseases in healthy adults. Researchers will compare LC-Plasma to placebo, participants will take a tablet containing LC-Plasma or placebo daily for 4 weeks.

Conditions

• Healthy Volunteer
• Immune Response

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	LC-Plasma	1 tablet containing 50mg LC-Plasma is taken daily for 4 weeks
OTHER	Placebo	1 tablet containing 50mg MCC is taken daily for 4 weeks

Timeline

• Start date: 2025-04-29
• Primary completion: 2025-11-03
• Completion: 2025-11-03
• First posted: 2025-02-20
• Last updated: 2025-11-18

Locations

1 site across 1 country: Australia